Zobrazeno 1 - 10 of 62 pro vyhledávání: '"Lewcock, JW"'
1
Loss of dual leucine zipper kinase signaling is protective in animal models of neurodegenerative disease
Autor: Le Pichon, CE, Meilandt, WJ, Dominguez, S, Solanoy, H, Lin, H, Ngu, H, Gogineni, A, Ghosh, AS, Jiang, Z, Lee, S-H, Maloney, J, Gandham, VD, Pozniak, CD, Wang, B, Lee, S, Siu, M, Patel, S, Modrusan, Z, Liu, X, Rudhard, Y, Baca, M, Gustafson, A, Kaminker, J, Carano, RAD, Huang, EJ, Foreman, O, Weimer, R, Scearce-Levie, K, Lewcock, JW, Sease, Neurodegenerative
Publikováno v: Le Pichon, CE; Meilandt, WJ; Dominguez, S; Solanoy, H; Lin, H; Ngu, H; et al.(2017). Loss of dual leucine zipper kinase signaling is protective in animal models of neurodegenerative disease. SCIENCE TRANSLATIONAL MEDICINE, 9(403). doi: 10.1126/scitranslmed.aag0394. UC San Francisco: Retrieved from: http://www.escholarship.org/uc/item/1481v5tb
Hallmarks of chronic neurodegenerative disease include progressive synaptic loss and neuronal cell death, yet the cellular pathways that underlie these processes remain largely undefined. We provide evidence that dual leucine zipper kinase (DLK) is a
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::ee82a5ec36d230fae12b7afd234dd385
http://www.escholarship.org/uc/item/1481v5tb
Zobrazit plný text záznamu
2
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
3
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
4
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
5
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
6
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
7
Akademický článek
Decreased lipidated ApoE-receptor interactions confer protection against pathogenicity of ApoE and its lipid cargoes in lysosomes.
Autor: Guo JL; Denali Therapeutics Inc., South San Francisco, CA, USA. Electronic address: guojing84@hotmail.com., Braun D; Denali Therapeutics Inc., South San Francisco, CA, USA., Fitzgerald GA; Denali Therapeutics Inc., South San Francisco, CA, USA., Hsieh YT; Denali Therapeutics Inc., South San Francisco, CA, USA., Rougé L; Denali Therapeutics Inc., South San Francisco, CA, USA., Litvinchuk A; Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA., Steffek M; Denali Therapeutics Inc., South San Francisco, CA, USA., Propson NE; Denali Therapeutics Inc., South San Francisco, CA, USA., Heffner CM; Denali Therapeutics Inc., South San Francisco, CA, USA., Discenza C; Denali Therapeutics Inc., South San Francisco, CA, USA., Han SJ; Denali Therapeutics Inc., South San Francisco, CA, USA., Rana A; Denali Therapeutics Inc., South San Francisco, CA, USA., Skuja LL; Denali Therapeutics Inc., South San Francisco, CA, USA., Lin BQ; Denali Therapeutics Inc., South San Francisco, CA, USA., Sun EW; Denali Therapeutics Inc., South San Francisco, CA, USA., Davis SS; Denali Therapeutics Inc., South San Francisco, CA, USA., Balasundar S; Denali Therapeutics Inc., South San Francisco, CA, USA., Becerra I; Denali Therapeutics Inc., South San Francisco, CA, USA., Dugas JC; Denali Therapeutics Inc., South San Francisco, CA, USA., Ha C; Denali Therapeutics Inc., South San Francisco, CA, USA., Hsiao-Nakamoto J; Denali Therapeutics Inc., South San Francisco, CA, USA., Huang F; Denali Therapeutics Inc., South San Francisco, CA, USA., Jain S; Denali Therapeutics Inc., South San Francisco, CA, USA., Kung JE; Denali Therapeutics Inc., South San Francisco, CA, USA., Liau NPD; Denali Therapeutics Inc., South San Francisco, CA, USA., Mahon CS; Denali Therapeutics Inc., South San Francisco, CA, USA., Nguyen HN; Denali Therapeutics Inc., South San Francisco, CA, USA., Nguyen N; Denali Therapeutics Inc., South San Francisco, CA, USA., Samaddar M; Denali Therapeutics Inc., South San Francisco, CA, USA., Shi Y; Denali Therapeutics Inc., South San Francisco, CA, USA., Tatarakis D; Denali Therapeutics Inc., South San Francisco, CA, USA., Tian Y; Denali Therapeutics Inc., South San Francisco, CA, USA., Zhu Y; Denali Therapeutics Inc., South San Francisco, CA, USA., Suh JH; Denali Therapeutics Inc., South San Francisco, CA, USA., Sandmann T; Denali Therapeutics Inc., South San Francisco, CA, USA., Calvert MEK; Denali Therapeutics Inc., South San Francisco, CA, USA., Arguello A; Denali Therapeutics Inc., South San Francisco, CA, USA., Kane LA; Denali Therapeutics Inc., South San Francisco, CA, USA., Lewcock JW; Denali Therapeutics Inc., South San Francisco, CA, USA., Holtzman DM; Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA., Koth CM; Denali Therapeutics Inc., South San Francisco, CA, USA., Di Paolo G; Denali Therapeutics Inc., South San Francisco, CA, USA. Electronic address: dipaolo@dnli.com.
Publikováno v: Cell [Cell] 2024 Nov 11. Date of Electronic Publication: 2024 Nov 11.
Zobrazit plný text záznamu
8
Akademický článek
DNL343 is an investigational CNS penetrant eukaryotic initiation factor 2B activator that prevents and reverses the effects of neurodegeneration caused by the integrated stress response.
Autor: Yulyaningsih E; Denali Therapeutics, South San Francisco, United States., Suh JH; Denali Therapeutics, South San Francisco, United States., Fanok M; Denali Therapeutics, South San Francisco, United States., Chau R; Denali Therapeutics, South San Francisco, United States., Solanoy H; Denali Therapeutics, South San Francisco, United States., Takahashi R; Denali Therapeutics, South San Francisco, United States., Bakardjiev AI; Denali Therapeutics, South San Francisco, United States., Becerra I; Denali Therapeutics, South San Francisco, United States., Benitez NB; Denali Therapeutics, South San Francisco, United States., Chiu CL; Denali Therapeutics, South San Francisco, United States., Davis SS; Denali Therapeutics, South San Francisco, United States., Dowdle WE; Denali Therapeutics, South San Francisco, United States., Earr T; Denali Therapeutics, South San Francisco, United States., Estrada AA; Denali Therapeutics, South San Francisco, United States., Gill A; Denali Therapeutics, South San Francisco, United States., Ha C; Denali Therapeutics, South San Francisco, United States., Haddick PCG; Denali Therapeutics, South San Francisco, United States., Henne KR; Denali Therapeutics, South San Francisco, United States., Larhammar M; Denali Therapeutics, South San Francisco, United States., Leung AW; Denali Therapeutics, South San Francisco, United States., Maciuca R; Denali Therapeutics, South San Francisco, United States., Memarzadeh B; Denali Therapeutics, South San Francisco, United States., Nguyen HN; Denali Therapeutics, South San Francisco, United States., Nugent AA; Denali Therapeutics, South San Francisco, United States., Osipov M; Denali Therapeutics, South San Francisco, United States., Ran Y; Denali Therapeutics, South San Francisco, United States., Rebadulla K; Denali Therapeutics, South San Francisco, United States., Roche E; Denali Therapeutics, South San Francisco, United States., Sandmann T; Denali Therapeutics, South San Francisco, United States., Wang J; Denali Therapeutics, South San Francisco, United States., Lewcock JW; Denali Therapeutics, South San Francisco, United States., Scearce-Levie K; Denali Therapeutics, South San Francisco, United States., Kane LA; Denali Therapeutics, South San Francisco, United States., Sanchez PE; Denali Therapeutics, South San Francisco, United States.
Publikováno v: ELife [Elife] 2024 Sep 17; Vol. 12. Date of Electronic Publication: 2024 Sep 17.
Zobrazit plný text záznamu
9
Akademický článek
Targeting the transferrin receptor to transport antisense oligonucleotides across the mammalian blood-brain barrier.
Autor: Barker SJ; Denali Therapeutics Inc., South San Francisco, CA, USA., Thayer MB; Denali Therapeutics Inc., South San Francisco, CA, USA., Kim C; Denali Therapeutics Inc., South San Francisco, CA, USA., Tatarakis D; Denali Therapeutics Inc., South San Francisco, CA, USA., Simon MJ; Denali Therapeutics Inc., South San Francisco, CA, USA., Dial R; Denali Therapeutics Inc., South San Francisco, CA, USA., Nilewski L; Denali Therapeutics Inc., South San Francisco, CA, USA., Wells RC; Denali Therapeutics Inc., South San Francisco, CA, USA., Zhou Y; Denali Therapeutics Inc., South San Francisco, CA, USA., Afetian M; Ionis Pharmaceuticals, Carlsbad, CA, USA., Akkapeddi P; Denali Therapeutics Inc., South San Francisco, CA, USA., Chappell A; Ionis Pharmaceuticals, Carlsbad, CA, USA., Chew KS; Denali Therapeutics Inc., South San Francisco, CA, USA., Chow J; Denali Therapeutics Inc., South San Francisco, CA, USA., Clemens A; Denali Therapeutics Inc., South San Francisco, CA, USA., Discenza CB; Denali Therapeutics Inc., South San Francisco, CA, USA., Dugas JC; Denali Therapeutics Inc., South San Francisco, CA, USA., Dwyer C; Ionis Pharmaceuticals, Carlsbad, CA, USA., Earr T; Denali Therapeutics Inc., South San Francisco, CA, USA., Ha C; Denali Therapeutics Inc., South San Francisco, CA, USA., Ho YS; Denali Therapeutics Inc., South San Francisco, CA, USA., Huynh D; Denali Therapeutics Inc., South San Francisco, CA, USA., Lozano EI; Denali Therapeutics Inc., South San Francisco, CA, USA., Jayaraman S; Denali Therapeutics Inc., South San Francisco, CA, USA., Kwan W; Denali Therapeutics Inc., South San Francisco, CA, USA., Mahon C; Denali Therapeutics Inc., South San Francisco, CA, USA., Pizzo M; Denali Therapeutics Inc., South San Francisco, CA, USA., Robles-Colmenares Y; Denali Therapeutics Inc., South San Francisco, CA, USA., Roche E; Denali Therapeutics Inc., South San Francisco, CA, USA., Sanders L; Denali Therapeutics Inc., South San Francisco, CA, USA., Stergioulis A; Denali Therapeutics Inc., South San Francisco, CA, USA., Tong R; Denali Therapeutics Inc., South San Francisco, CA, USA., Tran H; Denali Therapeutics Inc., South San Francisco, CA, USA., Zuchero Y; Denali Therapeutics Inc., South San Francisco, CA, USA., Estrada AA; Denali Therapeutics Inc., South San Francisco, CA, USA., Gadkar K; Denali Therapeutics Inc., South San Francisco, CA, USA., Koth CMM; Denali Therapeutics Inc., South San Francisco, CA, USA., Sanchez PE; Denali Therapeutics Inc., South San Francisco, CA, USA., Thorne RG; Denali Therapeutics Inc., South San Francisco, CA, USA., Watts RJ; Denali Therapeutics Inc., South San Francisco, CA, USA., Sandmann T; Denali Therapeutics Inc., South San Francisco, CA, USA., Kane LA; Denali Therapeutics Inc., South San Francisco, CA, USA., Rigo F; Ionis Pharmaceuticals, Carlsbad, CA, USA., Dennis MS; Denali Therapeutics Inc., South San Francisco, CA, USA., Lewcock JW; Denali Therapeutics Inc., South San Francisco, CA, USA., DeVos SL; Denali Therapeutics Inc., South San Francisco, CA, USA.
Publikováno v: Science translational medicine [Sci Transl Med] 2024 Aug 14; Vol. 16 (760), pp. eadi2245. Date of Electronic Publication: 2024 Aug 14.
Zobrazit plný text záznamu
10
Akademický článek
Peripheral expression of brain-penetrant progranulin rescues pathologies in mouse models of frontotemporal lobar degeneration.
Autor: Reich M; German Center for Neurodegenerative Diseases (DZNE), 81377 Munich, Germany.; Graduate School of Systemic Neurosciences (GSN), LMU Munich, 82152 Planegg, Germany.; Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, 81377 Munich, Germany., Simon MJ; Denali Therapeutics Inc., South San Francisco, CA 94080, USA., Polke B; Metabolic Biochemistry, Biomedical Centre (BMC), Faculty of Medicine, LMU Munich, 81377 Munich, Germany., Paris I; Metabolic Biochemistry, Biomedical Centre (BMC), Faculty of Medicine, LMU Munich, 81377 Munich, Germany., Werner G; Metabolic Biochemistry, Biomedical Centre (BMC), Faculty of Medicine, LMU Munich, 81377 Munich, Germany., Schrader C; Metabolic Biochemistry, Biomedical Centre (BMC), Faculty of Medicine, LMU Munich, 81377 Munich, Germany., Spieth L; German Center for Neurodegenerative Diseases (DZNE), 81377 Munich, Germany.; Institute of Neuronal Cell Biology, Technical University Munich, 80802 Munich, Germany.; Max Planck Institute for Multidisciplinary Sciences, 37077 Göttingen, Germany., Davis SS; Denali Therapeutics Inc., South San Francisco, CA 94080, USA., Robinson S; Graduate School of Systemic Neurosciences (GSN), LMU Munich, 82152 Planegg, Germany.; Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, 81377 Munich, Germany.; Metabolic Biochemistry, Biomedical Centre (BMC), Faculty of Medicine, LMU Munich, 81377 Munich, Germany., de Melo GL; Denali Therapeutics Inc., South San Francisco, CA 94080, USA., Schlaphoff L; German Center for Neurodegenerative Diseases (DZNE), 81377 Munich, Germany.; Graduate School of Systemic Neurosciences (GSN), LMU Munich, 82152 Planegg, Germany.; Institute of Neuronal Cell Biology, Technical University Munich, 80802 Munich, Germany., Buschmann K; Metabolic Biochemistry, Biomedical Centre (BMC), Faculty of Medicine, LMU Munich, 81377 Munich, Germany., Berghoff S; German Center for Neurodegenerative Diseases (DZNE), 81377 Munich, Germany.; Institute of Neuronal Cell Biology, Technical University Munich, 80802 Munich, Germany.; Max Planck Institute for Multidisciplinary Sciences, 37077 Göttingen, Germany., Logan T; Denali Therapeutics Inc., South San Francisco, CA 94080, USA., Nuscher B; Metabolic Biochemistry, Biomedical Centre (BMC), Faculty of Medicine, LMU Munich, 81377 Munich, Germany., de Weerd L; German Center for Neurodegenerative Diseases (DZNE), 81377 Munich, Germany., Edbauer D; German Center for Neurodegenerative Diseases (DZNE), 81377 Munich, Germany.; Munich Cluster for Systems Neurology (Synergy), 81377 Munich, Germany., Simons M; German Center for Neurodegenerative Diseases (DZNE), 81377 Munich, Germany.; Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, 81377 Munich, Germany.; Institute of Neuronal Cell Biology, Technical University Munich, 80802 Munich, Germany.; Munich Cluster for Systems Neurology (Synergy), 81377 Munich, Germany., Suh JH; Denali Therapeutics Inc., South San Francisco, CA 94080, USA., Sandmann T; Denali Therapeutics Inc., South San Francisco, CA 94080, USA., Kariolis MS; Denali Therapeutics Inc., South San Francisco, CA 94080, USA., DeVos SL; Denali Therapeutics Inc., South San Francisco, CA 94080, USA., Lewcock JW; Denali Therapeutics Inc., South San Francisco, CA 94080, USA., Paquet D; Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, 81377 Munich, Germany.; Munich Cluster for Systems Neurology (Synergy), 81377 Munich, Germany., Capell A; German Center for Neurodegenerative Diseases (DZNE), 81377 Munich, Germany.; Metabolic Biochemistry, Biomedical Centre (BMC), Faculty of Medicine, LMU Munich, 81377 Munich, Germany., Di Paolo G; Denali Therapeutics Inc., South San Francisco, CA 94080, USA., Haass C; German Center for Neurodegenerative Diseases (DZNE), 81377 Munich, Germany.; Metabolic Biochemistry, Biomedical Centre (BMC), Faculty of Medicine, LMU Munich, 81377 Munich, Germany.; Munich Cluster for Systems Neurology (Synergy), 81377 Munich, Germany.
Publikováno v: Science translational medicine [Sci Transl Med] 2024 Jun 05; Vol. 16 (750), pp. eadj7308. Date of Electronic Publication: 2024 Jun 05.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje